Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial

Micro-Abstract Cisplatin with pemetrexed followed by maintenance pemetrexed and carboplatin with paclitaxel and bevacizumab followed by maintenance bevacizumab, standard first-line therapy for advanced nonsquamous non–small-cell lung cancer, were compared. Quality of life (QoL) at 12 weeks of mainte...

Full description

Saved in:
Bibliographic Details
Published inClinical lung cancer Vol. 16; no. 4; pp. 262 - 273
Main Authors Galetta, Domenico, Cinieri, Saverio, Pisconti, Salvatore, Gebbia, Vittorio, Morabito, Alessandro, Borsellino, Nicola, Maiello, Evaristo, Febbraro, Antonio, Catino, Annamaria, Rizzo, Pietro, Montrone, Michele, Misino, Andrea, Logroscino, Antonio, Rizzi, Daniele, Di Maio, Massimo, Colucci, Giuseppe
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2015
Subjects
Adult
Advanced NSCLC
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - administration & dosage
Carboplatin - administration & dosage
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Cisplatin - administration & dosage
EQ5D
Female
Hematology, Oncology and Palliative Medicine
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Neoplasm Staging
Paclitaxel - administration & dosage
Pemetrexed - administration & dosage
Pulmonary/Respiratory
Quality of Life
Symptom palliation
Treatment choice
Treatment Outcome
EQ5D
Treatment choice
Advanced NSCLC
Symptom palliation
Quality of life
Online AccessGet full text

Cover

More Information
Summary:Micro-Abstract Cisplatin with pemetrexed followed by maintenance pemetrexed and carboplatin with paclitaxel and bevacizumab followed by maintenance bevacizumab, standard first-line therapy for advanced nonsquamous non–small-cell lung cancer, were compared. Quality of life (QoL) at 12 weeks of maintenance, measured using the EuroQoL 5 Dimensions (EQ5D) Index and EQ5D-visual analogue scale, was the primary end point. QoL did not differ between these regimens. Comorbidities and other factors should help in deciding first-line treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2014.12.002